Tags : Priority approval

Merck’s Keytruda sBLA Receives FDA Priority Review for Treatment of

Vartika Singh September 4, 2018

Shots: The sBLA is based on P-II KEYNOTE-017 study including ORR and DOR for 1L merkel cell carcinoma(MCC), study shows most DTC in MCC patients The US has set a […]readmore

Tags : Priority approval

Merck’s Keytruda sBLA Receives FDA Priority Review for Treatment of

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : Priority approval

Merck’s Keytruda sBLA Receives FDA Priority Review for Treatment of

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company